Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06129240 · ClinicalTrials.gov registry record
An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH
A clinical trial of Pulmonary Hypertension and Interstitial Lung Disease, sponsored by Liquidia Technologies.
- Active
- Registry status
- 80
- Enrollment target
- 18
- Study locations
NCT06129240: Active study of Pulmonary Hypertension and Interstitial Lung Disease, sponsored by Liquidia Technologies.
NCT06129240 is a study of Pulmonary Hypertension and Interstitial Lung Disease that is active but no longer recruiting, run by Liquidia Technologies. The registered enrollment target is 80 participants, below the 613-participant average among 72 other Pulmonary Hypertension trials with a reported enrollment target (87% lower). The trial reports 18 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06129240, a study of Pulmonary Hypertension and Interstitial Lung Disease, is active but no longer recruiting, sponsored by Liquidia Technologies.
- ACTIVE NOT RECRUITING
- Registry status
- 80 participants
- Enrollment target
- 18
- Study locations
Study Summary
Study LTI-401 is an open-label, multicenter study which will evaluate the safety and tolerability of LIQ861 in subjects who have WHO Group 1 \& 3 PH.
Primary Outcome
Treatment-emergent AEs and SAEs will be grouped by MedDRA System Organ Class, dose level at onset, time on drug at onset, and relationship to dose titration. Device-related AEs and SAEs will be grouped by MedDRA System Organ Class, dose level at onset, time on drug at onset, and relationship to dose titration.
Conditions Studied
Interventions
- DRUG LIQ861
Study Locations (18)
California
- The Medical Research Group, Inc. - Fresno
- UCLA Westwood - Los Angeles
- UC Davis - Sacramento
- UCSF - San Francisco
Florida
- Advent Health - Orlando
- Tampa General Hospital Center of Research Excellence - Tampa
New York
- NYU Langone Medical Center - New York
- University of Rochester - Rochester
Arizona
- Arizona Pulmonary Specialists - Phoenix
Colorado
- National Jewish Health - Denver
Indiana
- Vincent Medical Group - Indianapolis
Michigan
- University of Michigan - Ann Arbor
Minnesota
- University of Minnesota - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2023-12-28 |
| Est. Completion | 2028-02-08 |
What the registry record for NCT06129240 still lists
NCT06129240 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 613-participant average among 72 other Pulmonary Hypertension trials with a reported enrollment target (87% lower).
The record links to 2 conditions, with Pulmonary Hypertension appearing as the primary indexed condition, and to 1 intervention - of which LIQ861 is the first listed.
NCT06129240 lists 18 locations in 13 states (California, Florida, New York).
Frequently Asked Questions
What is clinical trial NCT06129240 about?
NCT06129240 is a clinical study titled "An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH". Study LTI-401 is an open-label, multicenter study which will evaluate the safety and tolerability of LIQ861 in subjects who have WHO Group 1 \& 3 PH.
What is the current status of trial NCT06129240?
This trial is currently active not recruiting. The enrollment target is 80 participants. The study started on 2023-12-28. Estimated completion is 2028-02-08.
What conditions does trial NCT06129240 study?
This clinical trial studies the following conditions: Pulmonary Hypertension, Interstitial Lung Disease.
What interventions are being tested in trial NCT06129240?
The interventions under investigation include: LIQ861 (DRUG).
Who is sponsoring clinical trial NCT06129240?
This trial is sponsored by Liquidia Technologies, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06129240 being conducted?
This trial has 18 study locations across Arizona, California, Colorado, Florida, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06129240's enrollment target sits among peer trials
80 34th of 72 higher than 39 of 72 other Pulmonary Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pulmonary Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection
RECRUITING
-
Development of an Algorithm to Detect Pulmonary Hypertension Using an Electronic Stethoscope
RECRUITING
-
Treatment of Pulmonary Arterial Hypertension Using the Aria CV Pulmonary Hypertension System
RECRUITING · NA
-
Heart Institute Biobank & Registry for Adult Congenital Heart Disease and Related Disorders
RECRUITING
-
LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF
RECRUITING · Phase 3
-
Hemodynamic Assessment of underLying myocyTe Function in Right Heart Failure
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI